Date: July 10, 2026

Business Update Summary

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders, announced its participation at the Alzheimer's Association International Conference (AAIC) 2026, to be held during July 12-15, 2026, in London, United Kingdom.

Conference Participation Details

The company will present five scientific posters at the conference, which is described as the largest international conference dedicated to advancing dementia science and clinical practice. The presentations will include:

  • Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SUVN-I6107, a M1 PAM, in Healthy Human Subjects (Sunday-0178, 12th July, 7:30 AM - 4.15 PM)
  • SUVN-L1101142: A Muscarinic 4 Positive Allosteric Modulator for the Treatment of Alzheimer's Disease and Schizophrenia (Monday-0321, 13th July, 7:30 AM - 4:15 PM)
  • Masupirdine (A Pure 5-HT6R Antagonist): Updates from the Phase-3 Clinical Trial Program Targeting Agitation in Alzheimer's Dementia (Wednesday-0043, 15th July, 7:30 AM - 4:15 PM)
  • Usmarapride, selective 5-HT4R partial agonist: an update on the clinical development program for the treatment of cognitive disorders (Wednesday-0436, 15th July, 7:30 AM - 4:15 PM)
  • Efficacy and Safety of SUVN-N9503012, a Selective 5-HT1A Partial Agonist for the Symptomatic Treatment of Neurodegenerative Disorders (Wednesday-0943, 15th July, 7:30 AM - 4:15 PM)

Strategic Objectives

The company will showcase broader non-clinical and clinical research advances across its neuroscience pipeline and engage with investigators, key opinion leaders, and the global research community. Suven will also explore strategic partnering opportunities for its clinical-stage CNS portfolio with pharmaceutical and biotechnology companies.

Conference attendees are invited to visit Suven's Exhibit Booth #117, where members of the Company's scientific and business development teams will be available throughout the meeting.

Company Pipeline Overview

Suven Life Sciences has a portfolio of advanced stage clinical candidates and research programs designed for CNS disorders including:

  • Masupirdine (SUVN-502) for treatment of agitation in patients with dementia of the Alzheimer's type (Global Phase-3 study ongoing)
  • Samelisant (SUVN-G3031) for treatment of narcolepsy (Phase-2 study for EDS completed; Phase-2 study for Cataplexy and pivotal Phase-3 study for EDS are in planning)
  • Ropanicant (SUVN-911) for MDD (Open-label Phase-2a study completed; Double blind randomized Placebo controlled Phase-2b proof of concept study completed)
  • Usmarapride (SUVN-D4010) for cognitive disorders (Phase-2 study in planning)
  • SUVN-I6107 for cognitive disorders (Phase-1 study completed)

The company also has 7 projects in research pipeline across multiple indications and owns all intellectual property rights for its assets in all major markets.